Is there an adverse effect of the use of losartan potassium on the left ventricular thickness of the heart of rats?
DOI:
https://doi.org/10.33448/rsd-v11i14.35417Keywords:
Losartan; Heart; Left ventricle; Heart muscle.Abstract
Losartan potassium is a drug indicated mostly for the treatment of hypertension. The worrisome factor in relation to the side effects of the administration of this drug in the heart, is due to its chronic or indistinct use. Therefore, to investigate the possible damages resulting from this drug, the aim of this study is to analyze, morphometrically, the thickness of the left ventricular layer of the heart of rats treated with different dosages of Losartana and to investigate its possible harmful effects. For this achievement, samples of adult male Wistar rats already belonging to the histological collection of research of the Department of Anatomy of ICB/Unifal-MG were used. The animals were divided into 5 five groups in which they received the following doses: Control group; G10 - treated with Losartan at a dose of 10 mg/kg/day; G30 - treated with Losartan at a dose of 30 mg/kg/day; G50 - treated with Losartan at a dose of 50 mg/kg/day and G70 - treated with Losartan at a dose of 70mg/kg/day. After 14 days of treatment, the animals were euthanized and their hearts removed and processed following the standardized histological procedure. For morphometric analysis, 9 distinct cuts of the heart were selected. Through specific software, left ventricular thickness was measured in μm2 and statistical analysis was performed by means of variance analysis followed by the Tukey test. Based on the results obtained, it was concluded that the use of Losartan in the doses and treatment conditions of this study did not cause significant changes in the left ventricle of the heart.
References
Avanza JR, A. C., El Aouar, L. M., & Mill, J. G. (2000) Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan. Arquivos Brasileiros de Cardiologia, 74(2), 111–117.
Barroso, W. K. S., Rodrigues, C. I. S., Bortolotto, L. A., Mota-Gomes, M. A., Brandão, A. A., Feitosa, A. D. M. et al. (2021). Diretrizes Brasileiras de Hipertensão Arterial. Arquivos Brasileiros de Cardiologia, 116(3), 516-658.
Brasil. (2019). Hipertensão é diagnosticada em 24,7% da população, segundo a pesquisa Vigitel. Ministério da Saúde. Pesquisa: https://antigo.saude.gov.br/noticias/agencia-saude/45446-no-brasil-388-pessoas-morrem-por-dia-por-hipertensao
Donmez, B.O., Unal, M., Ozdemir, S. et al. (2017) Effects of losartan treatment on the physicochemical properties of diabetic rat bone. J Bone Miner Metab 35, 161–170.
El-Ashmawy, N.E., El-Bahrawy, H.A., Shamloula, M.M. & Ibrahim, A.O. (2015), Antifibrotic effect of AT-1 blocker and statin in rats with hepatic fibrosis. Clin Exp Pharmacol Physiol, 42: 979-987.
Fernandes, G.O.R. et al, (2017) Pharmacological effects around the AT1 receptor block. Revista Científica FAEMA, 8 (2), 2179-4200
Fountain, J. H.; Lappin, S. L. (2021) Physiology, Renin Angiotensin System. [s.l.] StatPearls Publishing.
Gerdts, E., Björnstad, H., Devereux, R. B., Lund-Jhansen, P., Davidsen,E. S., & Omvik, P. (2006) Exercise performance during losartan‐ or atenolol‐based treatment in hyperten- sive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy). Blood Pressure, 15(4), 220–226.
Giestas, A. et al, (2010) Sistema renina-angiotensina-aldosterona e sua modulação farmacológica, Acta Med Port. 23(4):677-688
Gonsalez, S. R. et al. (2018) Inappropriate activity of local renin-angiotensin-aldosterone system during high salt intake: impact on thecardio-renal axis. Brazilian Journal of Nephrology 40(2), 170–178.
Guido, M. C. et al. (2019) Losartan diminui expressão de TGF-β e melhora a miocardiopatia em camundongos com síndrome de Marfan.Instituto de Biociências - USP.
Hernán Gómez Llambí, H. et al. (2017) Left ventricular hypertrophy does not prevent heart failure in experimental hypertension. International Journal of Cardiology, 238, 57–65.
Katsiki N, Tsioufis K, Ural D, & Volpe M. (2018) Fifteen years of LIFE (Losartan Intervention for Endpoint Reduction in Hypertension)-Lessons learned for losartan: An "old dog playing good tricks". J Clin Hypertens (Greenwich). 5;20(8):1153–9.
Laurent, S.; Boutouyrie, P. (2015) The structural factor of hypertension: large and small artery alterations. Circulation research, 116(6), 1007–21.
Le T, Crowley S, Gurley S & Coffman T. (2008) The Kidney Physiology and Pathophysiology. Elsevier. O Sistema Renina-Angiotensina; 343–357.
Lee, JJ., Galatioto, J., Rao, S. et al. (2016) Losartan Attenuates Degradation of Aorta and Lung Tissue Micromechanics in a Mouse Model ofSevere Marfan Syndrome. Ann Biomed Eng 44, 2994–3006.
Merck S. & Dohme (2019) Losartana Potássica. [Bula]. Farmacêutica Ltda.
Maciel, BC. (2001) A hipertrofia cardíaca na hipertensão arterial sistêmica: mecanismo compensatório e desencadeante de insuficiência cardíaca. Rev Bras Hipertens 8: 409-13.
Marks, LS. & Maxwell, MH. (1979) Tigerstedt and the Discovery of Renin An Historical. Hypertension 1(4), 384-388
Osborn, MJ. et al. (2016) Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology. J Inherit Metab Dis.
Patten, R. D. et al. (2003) Effects of angiotensin II receptor blockade versus angiotensinconverting-enzyme inhibition on ventricular remodelling following myocardial infarction in the mouse. Clin Sci (Lond); 104, 109–18.
Ribas, L. F. O.; & Guimarães, V. M. (2006) Avaliação da compreensão dos pacientes hipertensos a respeito da hipertensão arterial e seu tratamento versus controle pressórico. Revista Brasileira de Medicina de Família e Comunidade, 1(4), 152-164.
Silva, RP. Amodeo, C. & Ramires, JAF. (2002) Ventrículo direito e hipertensão arterial. Arq Bras Cardiol, 79 (3), 313-8.
Sociedade Brasileira de Cardiologia. (2020) Diretrizes Brasileiras de Hipertensão Arterial. Arq Bras Cardiol [Internet]. 2021; 116(3):516-658.
de Souza ELP, Dias RL, Rios RS, Vieira TM, Damião B, Rossi Junior WC, & Esteves A. (2019) Effects of Supraphysiological Doses of Steroids on the Left Ventricle of Sedentary Mice: Morphometric Analysis. Journal of Morphological Sciences 36(02), 91-96.
Veronez, L. L.; & Simões, M. J. S. (2008) Análise da prescrição de medicamentos de pacientes hipertensos atendidos pelo SUS da rede municipal de saúde de Rincão – SP. Revista de Ciências Farmacêuticas Básica e Aplicada, 29(1), 45-51.
Viegas, K. A. DA S. (2012) Ação da angiotensina II no remodelamento da matriz extracelular perivascular em camundongos. 2012. 109f. Tese (Doutorado), Universidade de São Paulo, São Paulo.
Vieira T. M, Rossi Junior W. C, Guerra F. D. R., Damião B, Marques P. P., & Esteves A. (2019) Effect of testosterone cypionate and stanozolol on the heart of young trained mice: A morphometric study, Steroids 145, 19-22
Wang, L.; LI, J.; & LI, D. (2015) Losartan reduces myocardial interstitial fibrosis in diabetic cardiomyopathy rats by inhibiting JAK/STAT signaling pathway. International journal of clinical and experimental pathology, 8(1), 466–73.
Watai, P. Y. (2020) Exercício Físico associado ao efeito do uso de losartana sobre a hipertrofia cardíaca em ratos espontaneamente hipertensos. Universidade Federal de Ouro Preto: Escola de Farmácia. https://www.monografias.ufop.br/bitstream/35400000/3192/8/MONOGRAFIA_ExercicioLosartanaHipertrofia.pdf
White M. (1999) Cardioprotective effect of angiotensin II receptor antagonists. Can J Cardiol.
World Health Organization. (2021) Hipertensão. Disponível: https://www.who.int/news-room/fact-sheets/detail/hypertension
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Lara Maria de Oliveira Delgado; Lavínia Vitória Candido ; Carla Cristina Esteves de Oliveira ; Flávia Da Ré Guerra; Wagner Costa Rossi Junior; Alessandra Esteves
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
